Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult‐onset spasticity
暂无分享,去创建一个
[1] S. Fahn,et al. Development of Antibodies to Botulinum Toxin Type A in Patients with Torticollis Treated with Injections of Botulinum Toxin Type A , 1993 .
[2] M. Brin,et al. BOTULINUM TOXIN FOR THE TREATMENT OF SPASTICITY IN MULTIPLE SCLEROSIS: New Observations , 1993, American journal of physical medicine & rehabilitation.
[3] S H Pierson,et al. Outcome measures in spasticity management , 1997, Muscle & nerve. Supplement.
[4] H. C. Wang,et al. The effect of acupuncture on spinal motor neuron excitability in stroke patients. , 1995, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.
[5] D M Simpson,et al. Traditional pharmacological treatments for spasticity part I: Local treatments , 1997, Muscle & nerve. Supplement.
[6] D. Simpson. Clinical trials of botulinum toxin in the treatment of spasticity , 1997, Muscle & nerve. Supplement.
[7] A. Cosgrove,et al. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. , 1994, Developmental medicine and child neurology.
[8] A. Esquenazi,et al. Common patterns of clinical motor dysfunction , 1997, Muscle & nerve. Supplement.
[9] J. Jankovic,et al. Botulinum toxin: Historical perspective and potential new indications , 1997, Muscle & nerve. Supplement.
[10] D. de Leon,et al. Proposed guidelines for videotaping individuals with movement disorders. , 1991, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[11] J. Janosky,et al. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. , 1993, JAMA.
[12] A. Cosgrove,et al. Botulinum Toxin A in the Hemiplegic Upper Limb: a Double‐Blind Trail , 1997, Developmental medicine and child neurology.
[13] C. O’Brien,et al. Injection techniques for botulinum toxin using electromyography and electrical stimulation , 1997, Muscle & nerve. Supplement.
[14] M. Brin. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology , 1997, Muscle & nerve. Supplement.
[15] N. O'dwyer,et al. REDUCTION OF SPASTICITY IN cérébral PALSY USING FEEDBACK OF THE TONIC STRE1CH REFLEX; A CONTROLLED STUDY , 1994, Developmental medicine and child neurology.
[16] K. Schwartz,et al. Response and immunoresistance to botulinum toxin injections , 1995, Neurology.
[17] B. Russman,et al. Cerebral palsy: A rational approach to a treatment protocol, and the role of botulinum toxin in treatment , 1997, Muscle & nerve. Supplement.
[18] S Fahn,et al. Development of resistance to botulinum toxin type A in patients with torticollis , 2004, Movement disorders : official journal of the Movement Disorder Society.
[19] R. Sloop,et al. Reconstituted Botulinum Toxin Type A Does Not Lose Potency in Humans If It Is Refrozen or Refrigerated for 2 Weeks Before Use , 1997, Neurology.
[20] L. Pearce,et al. Histologic assessment of dose‐related diffusion and muscle fiber response after therapeutic botulinum a toxin injections , 1994, Movement disorders : official journal of the Movement Disorder Society.
[21] K Albany,et al. Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity , 1997, Muscle & nerve. Supplement.
[22] D M Simpson,et al. Traditional pharmacological treatments for spasticity part II: General and regional treatments , 1997, Muscle & nerve. Supplement.
[23] N. Bathien,et al. Botulinum antibodies in dystonic patients treated with type A botulinum toxin , 1993, Neurology.